Klarity Kratom sold kratom products as unapproved drugs claiming they treat opioid addiction, FDA and FTC say.
What happened
FDA reviewed the website https://klaritykratom.com/ on May 31, 2022, and the Federal Trade Commission reviewed it in June 2022, and both found the company takes orders there for kratom products. The site carried claims that kratom eases opioid withdrawal, removes opioid effects, and helps rheumatoid arthritis symptoms, plus a customer review about giving up opioids. FDA says those claims make the products unapproved new drugs, and FTC says the addiction claims lack scientific support.
What FDA found
The website claims kratom treats opioid withdrawal, opioid addiction and arthritis symptoms, which makes the products drugs under the law.
Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)The products are not generally recognized as safe and effective for these uses, so they count as new drugs.
Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)The company sells these new drugs without an FDA-approved application, which is illegal.
Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)The company advertises that kratom can treat or cure opioid addiction without competent and reliable scientific evidence, which the FTC Act forbids.
FTC Act, 15 U.S.C. 41-57Deceptive claims about treating a substance use disorder can bring civil penalties of up to $46,517 per violation plus consumer refunds.
Section 8023 of the Opioid Addiction Recovery Fraud Prevention Act of 2018, 15 U.S.C. 45d
What FDA wants
FDA asks the company to write within 15 working days describing the specific steps taken to correct the violations and prevent recurrence, with supporting documents. FTC separately demands that the company immediately stop all addiction-treatment claims and report its actions to FTC within 15 working days.
Who should pay attention
- kratom brands and online retailers that make health claims
- marketers of herbal or botanical products claiming addiction or disease benefits
- e-commerce and payment platforms hosting such product listings
This is a summary. Read the original letter on fda.gov.